Can This Pharma CEO Change The Way Drugs Are Discovered, Developed, And Delivered With AI?

On October 27, 2023, Sanofi reported its earnings, generally beating the estimates. The company also announced that it will put more resources into internal R&D and spin off its consumer division to focus on innovative pharmaceuticals. The market interpreted the news in its own way, sending the stock back to November 2022 levels, erasing the hard-earned gains made during the past 12 months. Sanofi has remained among the top pharma performers year over year, but the twenty percent drop in a single day sent shockwaves throughout the industry despite gradual recovery.